SCHEMBL4720698

SCHEMBL4720698

COc1c(Cl)ncnc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
KMO O15229 1/20 0.40
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
DYRK3 O43781 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK2 Q92630 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
KIF11 P52732 1/20 0.37
GAK O14976 1/20 0.36
EGFR P00533 1/20 0.36
NPC1 O15118 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
KMT2A Q03164 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23147071 0.83 KMO (0.43) KMORAB9ASMN1; SMN2NPSR1NPC1
SCHEMBL6918405 0.81 KMO (0.43) KMORAB9ASMN1; SMN2NPSR1EGFR
SCHEMBL4720003 0.80 KIF11 (0.40) KMODYRK1ADYRK2KIF11MKNK1
SCHEMBL17393638 0.78 GAK (0.37) ALOX5APFEN1RAB9ANPSR1GAK
SCHEMBL9493312 0.73 KIF11 (0.47) DYRK1ADYRK2KIF11RPS6KB1
SCHEMBL18985690 0.73 KMO (0.46) KMORAB9AEGFRNPC1TDP1
SCHEMBL9607644 0.72 KMO (0.43) KMOKDM4E
SCHEMBL288911 0.70 ALDH1A1 (0.44) KMORAB9ASMN1; SMN2NPSR1EGFR
SCHEMBL3322318 0.68 KIF11 (0.50) RAB9ADYRK1ADYRK2KIF11NPC1
SCHEMBL12320477 0.68 KIF11 (0.46) KIF11MKNK1MKNK2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ALOX5AP 2123/4885FEN1 3748/4885KMO 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.